Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

The Emmy-nominated Tramell Tillman immediately blew his whistle, with the band striking up the Powerman 5000 song “Relax,” ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Old Forester is releasing the 25th version of the beloved Birthday Bourbon, and this year’s edition comes with a twist.

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) stock declined 4% in pre-market trading Monday after the FDA approved Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic metabolic ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Wegovy becomes the first GLP-1 based therapy authorized for MASH, which affects roughly 5% of U.S. adults, according to the ...